natgillin/translations-raw huggingface dataset:
These samples were chilled, homogenised and stored at -80°C until analysis 4 to 6 months later (storage stability confirmed).
Vzorce so ohladili, homogenizirali in do analize, 4 do 6 mesecev kasneje, hranili pri -80 °C (obstojnost skladiščenja potrjena).
For pigs of 40-50 kg, it was possible to derive a withdrawal period of 35 days based on injection site residues.
Pri prašičih, težkih 40-50 kg, je bila na podlagi ostankov na mestih injiciranja določena karenca 35 dni.
Sixteen pigs were slaughtered at 7, 14, 21 and 27 days after treatment with Suramox.
Šestnajst prašičev je bilo zaklanih 7, 14, 21 in 27 dni po zdravljenju z zdravilom Suramox.
All samples were analysed for amoxicillin concentrations using an HPLC-UV method (HPLC-fluorescence for liver) with a claimed limit of quantification of 25 µg/kg for all tissues.
Pri vseh vzorcih so analizirali koncentracije amoksicilina z metodo HPLC-UV (HPLC-fluorescenca za jetra) z zahtevano mejo kvantifikacije 25 µg/kg za vsa tkiva.
The results reported indicated residue values below the muscle MRL at all time points except for 1 animal at the last time point, which had a concentration of 6 times above the muscle MRL. For one animal the result at 30 days was not reported.
Rezultati, o katerih so poročali, so nakazovali vrednosti ostankov pod MRL za mišično maso ob vseh časovnih točkah, razen pri eni živali ob zadnji časovni točki, pri kateri je bila koncentracija šestkrat večja od MRL za mišično maso.
With the submission of the new residue studies for pigs the MAH proposed a withdrawal period of 38 days based on the two studies provided.
Ob predložitvi novih študij o ostankih zdravila za prašiče je imetnik dovoljenja za promet predlagal karenco 38 dni, temelječo na dveh predloženih študijah.
All samples were analysed for amoxicillin concentrations using an HPLC-UV method with a claimed limit of quantification of 25 µg/kg for all tissues.
Pri vseh vzorcih so analizirali koncentracije amoksicilina z metodo HPLC-UV z zahtevano mejo kvantifikacije 25 µg/kg za vsa tkiva.
Suramox 15% LA contains amoxicillin which is a beta lactam antibiotic belonging to the group of penicillins.
beta-laktamski antibiotik iz skupine penicilinov.
In addition, samples were taken from muscle (mixed sample of hindquarter/forequarter muscle), fat (mixed sample of perirenal/omental fat), the entire liver, both kidneys, and the right (final) injection site (approximate dimensions of 10 cm diameter and 6 cm depth).
Poleg tega so vzeli vzorce mišic (mešani vzorec zadnje in sprednje četrti), maščobe (mešani vzorec perirenalne maščobe/maščobe pečice), cela jetra, obe ledvici in desno (zadnje) mesto injiciranja (približne dimenzije 10 cm premera in 6 cm globine).
An alternative method could not be used because at the last time point residue concentrations at the injection site were up to 5 times the MRL for muscle.
Alternativne metode ni bilo mogoče uporabiti, ker so bile koncentracije ostankov na mestu injiciranja v zadnji časovni točki do petkrat višje od MRL za mišično maso.
In pigs ten male and ten female (bw 42 ± 7 kg) were given two intramuscular injections with Suramox 15% LA at a dose of 15 mg/kg bw (1 ml per 10 kg).
Pri prašičih je deset samcev in deset samic (tt 42 ± 7 kg) prejelo dve intramuskularni injekciji zdravila Suramox 15 % LA z odmerkom 15 mg/kg tt (1 ml na 10 kg).
In cattle ten male and ten female (body weight: 184 ± 24 kg) were given two intramuscular injections with Suramox 15% LA at a dose of 15 mg/kg bw (1 ml per 10 kg).
Pri govedu je deset samcev in deset samic (telesna teža: 184 ± 24 kg) prejelo dve intramuskularni injekciji zdravila Suramox 15 % LA z odmerkom 15 mg/kg tt (1 ml na 10 kg).
GROUNDS FOR SUSPENSION OF THE MARKETING AUTHORISATIONS
PODLAGA ZA UMIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
In addition, samples were taken from muscle (mixed sample of hindquarter/forequarter muscle), skin+fat in natural proportions, the entire liver, both kidneys, and the right (final) injection site (approximate dimensions of 10 cm diameter and 6 cm depth).
Poleg tega so vzeli vzorce mišic (mešan vzorec zadnje in sprednje četrti), kože in maščobe v naravnem razmerju, cela jetra, obe ledvici, in desno (zadnje) mesto injiciranja (približne dimenzije 10 cm premera in 6 cm globine).
The CVMP noted that the MAH excluded two observations as being outliers when calculating the withdrawal period.
CVMP je ugotovil, da je MAH pri izračunavanju karence izključil dva dobljena rezultata kot posamični napaki.
o in cattle, residue concentration at the injection site were still above the MRL at the last slaughter time point; o in pigs, residue concentrations in kidneys were still above the MRL at the last slaughter time point;
o so bile pri govedu koncentracije ostankov na mestu injiciranja v zadnji časovni točki, to je ob zakolu, še vedno višje od MRL; o so bile pri prašičih koncentracije ostankov v ledvicah še v zadnji časovni točki, to je ob zakolu, še vedno višje od MRL;
In the injection sites, the amoxicillin concentrations were 14209 to 109535 µg/kg at day 1, 358 to 5429 µg/kg at day 7, 182 to 2816 µg/kg at day 14, below the limit of quantification to 211 µg/kg at day 21 and below the limit of quantification to 38 µg/kg at day 27.
Na mestih injiciranja so bile koncentracije amoksicilina 14209 do 109535 µg/kg na 1. dan, 358 to 5429 µg/kg na 7. dan, 182 to 2816 µg/kg na 14. dan, pod mejo kvantifikacije do 211 µg/kg na 21. dan in pod mejo kvantifikacije do 38 µg/kg na 27. dan.
Therefore kidney was considered the tissue determining the withdrawal period.
Zato so bile ledvice upoštevane kot tkivo za določitev karence.
2.1 Calculation of withdrawal periods for Suramox 15% LA
2.1 Izračun karence za zdravilo Suramox 15 % LA
In kidney, amoxicillin concentrations were 5446 to 9896 µg/kg at day 1, 45 to 811 µg/kg at day 7, below the limit of quantification at day 14, below the limit of quantification to 180 µg/kg at day 21 and below the limit of quantification to 62 µg/kg at day 27.
V ledvicah so bile koncentracije amoksicilina 5446 do 9896 µg/kg 1. dan, 45 do 811 µg/kg na 7. dan, pod mejo kvantifikacije na 14. dan, pod mejo kvantifikacije do 180 µg/kg na 21. dan in pod mejo kvantifikacije do 62 µg/kg na 27. dan.
Thus, the MRLs established by the CVMP for benzylpenicillin were 50 µg/kg for edible tissues.
Tako je CVMP določil, da je najvišja mejna vrednost ostankov benzilpenicilina v užitnem tkivu 50 µg/kg..
Residues in muscle, fat, liver and kidney were below the MRL at all time points.
Ob vseh časovnih točkah so bili ostanki v mišični masi, maščevju, jetrih in ledvicah manjši od MRL.
150 mg/ml
150 mg/ml govedo, prašiči
Residues in the injection sites were high and still up to 5 times above the muscle MRL at the latest time point.
Ostanki na mestih injiciranja so bili visoki in ob zadnji časovni točki še vedno petkrat višji od MRL za mišično maso.
For cattle the injection site was the withdrawal time determining tissue and the residue concentrations of amoxicillin in the injection sites were still above the MRL at the last slaughter time point.
Pri govedu je bilo tkivo za določitev karence mesto injiciranja, vendar so bile koncentracije amoksicilina na mestih injiciranja še pri zadnji časovni točki (ob zakolu) višje od MRL.
One new GLP-study in cattle and two complementary GLP-residue studies in pigs were submitted during the procedure for the reconsideration of the opinion.
Med postopkom ponovne preučitve mnenja je bila predložena ena nova raziskava, skladna z dobro laboratorijsko prakso, pri govedu in dve dopolnilni raziskavi ostankov, skladni z dobro laboratorijsko prakso, pri prašičih.
Groups of 4 animals (2 male and 2 female) were slaughtered at 1, 7, 14, 21, and 36 days after the final injection.
Razpon vbrizgane količine je segal od 15,0 do 25,9 ml. Skupine po 4 živali (2 samca in 2 samici) so bile zaklane 1, 7, 14, 21 in 36 dni po zadnjem injiciranju.
Residues in muscle, fat and liver were below the MRL at all time points.
Ob vseh časovnih točkah so bili ostanki v mišični masi, maščevju in jetrih manjši od MRL.
However, the residues in kidney showed an irregular depletion profile and concentrations above the MRL were still observed at the last slaughter time point.
Vendar je profil izločanja ostankov v ledvicah nereden, koncentracije pa so bile še pri zadnji časovni točki (ob zakolu) višje od MRL.
Groups of 4 animals (2 male, 2 female) were slaughtered at 1, 7, 14, 21, and 27 days after the final injection.
Razpon vbrizgane količine je segal od 2,88 do 5,52 ml. Skupine po 4 živali (2 samca in 2 samici) so bile zaklane 1, 7, 14, 21 in 27 dni po zadnjem injiciranju.
In the injection sites, the amoxicillin concentrations were 5822 to 149831 µg/kg at day 1, below the limit of quantification to 21724 µg/kg at day 7, below the limit of quantification to 1651 µg/kg at day 14, below the limit of quantification to 472 µg/kg at day 21 and below the limit of quantification to 162 µg/kg at day 36.
kvantifikacije do 21724 µg/kg na 7. dan, pod mejo kvantifikacije do 1651 µg/kg na 14. dan, pod mejo kvantifikacije do 472 µg/kg na 21. dan in pod mejo kvantifikacije do 162 µg/kg na 36. dan.
France2
LA3
The statistical nor the alternative method could be used as at the last time point residues at the injection site were up to 6 times the MRL for muscle.
Ker so bile koncentracije ostankov na mestu injiciranja v zadnji časovni točki do šestkrat višje od MRL za mišično maso, ni bilo mogoče uporabiti ne statistične ne alternativne metode.
This summary was last updated on 14/01/2010.
Povzetek je bil nazadnje posodobljen dne 14/01/2010.
The European Commission granted a marketing authorisation valid throughout the European Union, for RESPIPORC FLU3 to IDT Biologika GmbH on 14/01/2010.
Evropska komisija je dovoljenje za promet z zdravilom RESPIPORC FLU3, veljavno po vsej Evropski uniji, odobrila družbi IDT Biologika GmbH dne 14/01/2010.
Sometimes, a slight increase in the rectal temperature might occur after vaccination.
Občasno se lahko po cepljenju prehodno rahlo poviša rektalna temperatura.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) RESPIPORC FLU3 EPAR summary for the public
EMEA/V/C/153 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) RESPIPORC FLU3 Povzetek EPAR za javnost
Other information about RESPIPORC FLU3:
Druge informacije o zdravilu RESPIPORC FLU3:
RESPIPORC FLU3 is a vaccine.
RESPIPORC FLU3 je cepivo.
RESPIPORC FLU3 is a vaccine that contains 3 different strains of swine influenza A virus which have been inactivated (killed).
RESPIPORC FLU3 je cepivo, ki vsebuje tri različne seve virusa prašičje gripe A, ki so bili inaktivirani (uničeni).
RESPIPORC FLU3 is a suspension for injection.
Zdravilo RESPIPORC FLU3 je suspenzija za injiciranje.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses.
Ob ponovni izpostavitvi virusom v prihodnosti bo imunski sistem tako hitreje tvoril protitelesa.
RESPIPORC FLU3 is also used to vaccinate pregnant sows following their first immunisation by giving them one dose 14 days prior to farrowing in order that the sows milk contains enough antibodies to help protect the piglets against swine influenza for at least 33 days after birth.
Zdravilo RESPIPORC FLU3 se uporablja tudi za cepljenje brejih svinj po zaključeni prvi imunizaciji, z dajanjem enega odmerka 14 dni pred prasitvijo, da mleko svinj vsebuje dovolj protiteles, ki pujske ščitijo pred prašičjo gripo vsaj 33 dni po rojstvu.
What benefit has RESPIPORC FLU3 shown during the studies?
Kakšne koristi je zdravilo RESPIPORC FLU3 izkazalo med študijami?
RESPIPORC FLU3 contains small amounts of a modified and then killed form of the pig's influenza virus that causes lesions and illness.
Zdravilo RESPIPORC FLU3 vsebuje majhne količine modificirane in zatem inaktivirane oblike virusa prašičje gripe, ki povzroča lezije in bolezen.
Use of the RESPIPORC FLU3 in pigs reduces clinical signs and reduces the amount of virus in the lungs after infection caused by swine influenza A virus.
Uporaba cepiva RESPIPORC FLU3 pri prašičih zmanjša klinične znake in količino virusa v pljučih po okužbi, ki jo povzroči virus prašičje gripe A.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of RESPIPORC FLU3 exceed the risks for the vaccination of pigs from the age of 56 days onwards inluding pregnant sows against swine influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical signs and viral lung load after infection and recommended that RESPIPORC FLU3 be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila RESPIPORC FLU3 za cepljenje prašičev od 56 dneva starosti naprej, vključno z brejimi svinjami, proti prašičji gripi, ki jo povzročajo podtipi H1N1, H3N2 in H1N2, za zmanjšanje kliničnih znakov in prisotnosti virusa v pljučih po okužbi večje od z njim povezanih tveganj, in priporočil, da se za zdravilo RESPIPORC FLU3 odobri dovoljenje za promet.
The effectiveness of RESPIPORC FLU3 has been studied in animals 56 days of age and older and in sows before and during pregnancy and these studies document that the vaccine protects against swine influenza.
Učinkovitost zdravila RESPIPORC FLU3 so proučevali pri prašičih, starejših od 56 dni, in pri svinjah pred in med brejostjo, te študije pa dokazujejo, da cepivo zagotavlja zaščito pred prašičjo gripo.
A slight swelling may occur after vaccination at the site of injection in a small number of pigs but this goes down within 2 days.
Pri majhnem številu prašičev se lahko na mestu injiciranja pojavi manjša oteklina, ki običajno izgine v 2 dneh.
What is the risk associated with RESPIPORC FLU3?
Kakšna tveganja so povezana z zdravilom RESPIPORC FLU3?
Why has RESPIPORC FLU3 been approved?
Zakaj je bilo zdravilo RESPIPORC FLU3 odobreno?
RESPIPORC FLU3 is used to vaccinate pigs including pregnant sows over the age of 56 days against swine influenza in order to help them clinically but also to reduce the amount of virus present in the lungs.
Zdravilo RESPIPORC FLU3 se uporablja za cepljenje prašičev od 56 dneva starosti naprej, vključno z brejimi svinjami, proti prašičji gripi za zmanjšanje kliničnih znakov in prisotnosti virusa v pljučih.
What is RESPIPORC FLU3?
Kaj je zdravilo RESPIPORC FLU3?
How has RESPIPORC FLU3 been studied?
Kako je bilo zdravilo RESPIPORC FLU3 raziskano?
How does RESPIPORC FLU3 work?
Kako zdravilo RESPIPORC FLU3 deluje?
What is RESPIPORC FLU3 used for?
Za kaj se zdravilo RESPIPORC FLU3 uporablja?
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
DODATEK POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Details of the operation of the surveillance programme/registry shall be agreed with the National Competent Authorities in each Member State.
O podrobnostih glede delovanja programa/registra nadzorovanja se je treba dogovoriti s pristojnimi državnimi organi v vsaki državi članici.
The data to be collected shall be agreed with the CHMP.
O zbiranju podatkov se je treba dogovoriti s CHMP.
• The need for regular pregnancy tests
• potrebno je redno izvajati teste nosečnosti
• That hormonal contraceptives on their own are not effective
• da samo hormonska kontracepcija ni učinkovita
The patient information booklet for patients prescribed Tracleer should include the following key elements:
Navodila za uporabo za bolnike, ki jim je predpisano zdravilo Tracleer, morajo vsebovati naslednje ključne elemente:
• Information about Tracleer
• podatke o zdravilu Tracleer
• That pregnant women must not take Tracleer
• da nosečnice ne smejo jemati zdravila Tracleer
The Member States shall ensure that the MAH shall set up a surveillance programme/registry to collect information on the demographics, safety and outcome data from patients prescribed Tracleer to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
Države članice zagotovijo, da IDIZ vzpostavi program/register nadzorovanja za zbiranje informacij o učinkih ter demografskih in varnostnih podatkih bolnikov, ki jim je bilo predpisano zdravilo Tracleer, da se zmanjša število novih razjed prstov pri bolnikih s sistemsko sklerozo ter dolgotrajno boleznijo razjed prstov.
• That women of child bearing potential must use effective contraception
• da morajo ženske v rodni dobi jemati učinkovito kontracepcijo
• That Tracleer is teratogenic in animals
• da je zdravilo Tracleer teratogeno za živali
The MAH shall agree the details of a controlled distribution system with the National Competent Authorities and must implement such programme nationally to ensure that prior to prescribing all health care professionals who intend to prescribe and/or dispense Tracleer are provided with a Prescriber Kit containing the following:
IDIZ se o podrobnostih nadzorovanega distribucijskega sistema dogovori s pristojnimi državnimi organi in mora tak program izvajati nacionalno in tako zagotovi, da imajo vsi strokovnjaki zdravstvenega varstva, ki nameravajo predpisati in/ali izdati zdravilo Tracleer, že pred predpisovanjem zagotovljeno opremo za predpisovanje, ki vsebuje:
• Patient Information Booklet/Patient Reminder Card
• navodilo za uporabo/kartico Opozorila za bolnika
• That Tracleer causes a decrease in haemoglobin and the need for regular blood tests
• da zdravilo Tracleer povzroča znižanje hemoglobina in je potrebno redno izvajati krvne analize
• That Tracleer is hepatotoxic and the need for regular monitoring of liver function
• da je zdravilo Tracleer hepatotoksično in je potrebno redno spremljati delovanje jeter
The MAH shall agree with each National Competent Authority the content of a "Reminder Letter" to all known prescribers of Tracleer, reminding them of the safety concerns with Tracleer in relation to pregnancy.
Imetnik dovoljenja za promet z zdravilom bo skupaj z nacionalnim pristojnim organom določil vsebino "Opomnika", s katerim bo vse zdravnike, za katere je znano, da predpisujejo zdravilo Tracleer, opomnil glede pomislekov v zvezi z varnostjo zdravila Tracleer med nosečnostjo.
12 hours before your operation.
12 ur po operaciji.
Operation or periods of limited mobility due to an illness
Ob operacijah ali obdobjih omejene mobilnosti zaradi bolezni
Do not use this medicine if you notice {description of the visible signs of deterioration}.
Tega zdravila ne uporabite, če opazite {opis vidnih znakov kvarjenja}.
• Benzyl alcohol
• Benzilalkohol
Pharmacotherapeutic group: Antithrombotic agent, heparin group, ATC code: B01A B05
Farmakoterapevtska skupina: antitrombotiki, heparinska skupina, oznaka ATC: B01A B05
(subcutaneous).
(subkutano).
This is a preservative.
To je konzervans.
swelling of your lips, face, throat or tongue.
oteklost ustnic, obraza, žrela ali jezika.
Do not use this medicine after the expiry date which is stated on the label.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pakiranju.
Detailed information on this medicinal product is available on the website of {name of MS Agency (link)}
Podrobne informacije o zdravilu so objavljene na spletni strani {ime agencije DČ (povezava)}
This reduction in the combined incidence was maintained after 30 days (from 23.3 to 19.8%; relative risk reduction of
To zmanjšanje skupne incidence se je ohranilo po 30 dneh (s 23,3 na 19,8 %, relativno zmanjšanje tveganja 15 %).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: {DD month YYYY} Date of latest renewal: {DD month YYYY}
Datum prve odobritve: {DD. mesec LLLL} Datum zadnjega podaljšanja: {DD. mesec LLLL}
These medicinal products differ in their manufacturing process, molecular weights, specific anti-Xa and antiIIa activities, units, dosage and clinical efficacy and safety.
Ta zdravila se med seboj razlikujejo po postopku izdelave, molekulski masi, specifični aktivnosti anti-Xa in anti-IIa, enotah, odmerjanju ter klinični učinkovitosti in varnosti.
• When you go home, you may need to continue to use LOVENOX (and associated names) and give it yourself (see instructions below on how to do this).
• Ko boste odšli domov, boste morda morali še naprej uporabljati zdravilo LOVENOX (in povezana imena) in si ga boste morali dajati sami (glejte spodnja navodila, kako to naredite).
DATE OF REVISION OF THE TEXT {MM/YYYY} {DD/MM/YYYY} {DD month YYYY}
DATUM ZADNJE REVIZIJE BESEDILA {MM. LLLL} {DD/MM/LLLL} {DD. mesec LLLL}
These anticoagulant activities are mediated through anti-thrombin III (ATIII) resulting in antithrombotic activities in humans.
Te antikoagulantne učinke posreduje antitrombin III (ATIII); posledica je antitrombotično delovanje pri človeku.
Operations and Anaesthetics
Operacije in anestezija
If you forget to use LOVENOX (and associated names) If you forget to give yourself a dose, have it as soon as you remember.
Če ste pozabili uporabiti zdravilo LOVENOX (in povezana imena) Če si pozabite dati odmerek, ga morate dati, čim se spomnite.
Stop using LOVENOX (and associated names) and talk to a doctor or nurse at once if you get any signs of a severe allergic reaction (such as difficulty breathing, swelling of the lips, mouth, throat or eyes).
Nehajte uporabljati zdravilo LOVENOX (in povezana imena) in se takoj posvetujte z zdravnikom ali medicinsko sestro, če se vam pojavi kakršen koli znak hude alergijske reakcije (na primer težko dihanje, oteklost ustnic, ust, žrela ali oči).
It should not be mixed or coadministered with other medications.
Ne smete ga mešati ali uporabiti sočasno z drugimi zdravili.
The 3,000 IU (30 mg) dose can then be directly injected into the IV line.
3.000 i.e. (30 mg) lahko potem neposredno injicirate v intravensko linijo.
Do not give yourself a double dose on the same day to make up for a forgotten dose.
Ne dajte si na en dan dvojnega odmerka,
This difference persisted at three months [13.8% vs 5.5% (n=23 vs 9), p=0.01].
Ta razlika se je ohranila tudi po treh mesecih [13,8 % v primerjavi s 5,5 % (n = 23 v primerjavi z 9), p = 0,01].
Like other similar medicines (medicines to reduce blood clotting), LOVENOX (and associated names) may cause bleeding which may potentially be life-threatening.
Tako kot druga podobna zdravila (zdravila proti strjevanju krvi) lahko tudi zdravilo LOVENOX (in povezana imena) povzroči krvavitve, ki so lahko celo smrtno nevarne.
Multiple Dose Vials:
Večodmerne viale:
The absolute bioavailability of enoxaparin sodium after SC injection, based on anti-Xa activity, is close to 100%.
Absolutna biološka uporabnost natrijevega enoksaparinata po subkutani injekciji je na podlagi aktivnosti anti-Xa skoraj 100 %.
• Rare: Cutaneous vasculitis*, skin necrosis* usually occurring at the injection site (these phenomena have been usually preceded by purpura or erythematous plaques, infiltrated and painful).
• Redki: Alopecija* • Redki: Kožni vaskulitis*, nekroza kože*, ki se po navadi pojavi na mestu injiciranja (pred temi pojavi so se po navadi razvili purpura ali infiltrirani in boleči eritematozni plaki).
Stopping blood clots forming in your blood in the following situations:
Ustavitev nastajanja krvnih strdkov v krvi v naslednjih okoliščinah:
Withdraw 30 mL from the infusion bag with a syringe and discard the liquid.
Iz infuzijske vrečke z brizgo odvzemite 30 ml in to tekočino zavrzite.
It is important for you to keep having LOVENOX (and associated names) injections until your doctor decides to stop them.
Pomembno je, da injekcije zdravila LOVENOX (in povezana imena) uporabljate, dokler vam zdravnik ne naroči, da prenehajte.
Important information about some of the ingredients of LOVENOX (and associated names) LOVENOX (and associated names) contains benzyl alcohol [benzyl alcohol content to be completed nationally].
Pomembne informacije o nekaterih sestavinah zdravila LOVENOX (in povezana imena) Zdravilo LOVENOX (in povezana imena) vsebuje benzilalkohol [vsebnost benzilalkohola dopolni država članica].
If you stop using LOVENOX (and associated names) If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.
Če ste prenehali uporabljati zdravilo LOVENOX (in povezana imena) Če imate kakšna dodatna vprašanja o uporabi tega zdravila, se obrnite na zdravnika, farmacevta ali medicinsko sestro.